Evidence map›Paper›PMID 40976747›Full record

ArticleEuropean urology oncology2026

Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy.

Philip Sutera, Kim Van der Eecken, Yang Song, Amol C Shetty, Elai Davicioni, James A Proudfoot, Alexander Hakansson, Keara English, Jarey Wang, Ozan Cem Guler and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Philip SuteraDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kim Van der EeckenDepartments of Pathology and Human Structure and Repair, Ghent University, Ghent, Belgium.
Yang SongInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Amol C ShettyInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Elai DavicioniVeracyte, San Diego, CA, USA.
James A ProudfootVeracyte, San Diego, CA, USA.
Alexander HakanssonVeracyte, San Diego, CA, USA.
Keara EnglishDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jarey WangDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ozan Cem GulerDepartment of Radiation Oncology, Baskent University, Ankara, Turkey.
Soha BazyarDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Sofie VerbekeDepartment of Pathology and Cancer Research Institute, Ghent University Hospital, Ghent, Belgium.
Jo Van DorpeDepartments of Pathology and Human Structure and Repair, Ghent University, Ghent, Belgium.
Valérie FonteyneDepartment of Radiation Oncology, Ghent University Hospital, Belgium.
Bram De LaereDepartment of Radiation Oncology, Ghent University Hospital, Belgium.
Lara HathoutDepartment of Radiation Oncology, Rutgers Cancer Institute, Rutgers University, New Brunswick, NJ, USA.
Ronald EnnisDepartment of Radiation Oncology, Rutgers Cancer Institute, Rutgers University, New Brunswick, NJ, USA.
Salma K JabbourDepartment of Radiation Oncology, Rutgers Cancer Institute, Rutgers University, New Brunswick, NJ, USA.
Biren SaraiyaDivision of Medical Oncology, Rutgers Cancer Institute, Rutgers University, New Brunswick, NJ, USA.
Ryan StephensonDivision of Medical Oncology, Rutgers Cancer Institute, Rutgers University, New Brunswick, NJ, USA.
Tina MayerDivision of Medical Oncology, Rutgers Cancer Institute, Rutgers University, New Brunswick, NJ, USA.
Mark MishraDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Zaker RanaDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Jason MolitorisDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Ana KiessDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Daniel Y SongDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Theodore DeWeeseDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kenneth J PientaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Phuoc T TranDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Alejandro BerlinPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Cem OnalDepartment of Radiation Oncology, Baskent University, Ankara, Turkey.
Piet OstDepartment of Radiation Oncology, Ghent University Hospital, Belgium.
Matthew P DeekDepartment of Radiation Oncology, Rutgers Cancer Institute, Rutgers University, New Brunswick, NJ, USA. Electronic address: matthewdeek@gmail.com.

Funding

Resource Sharing CoreU54CA273956 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Phuoc T. Tran · 2022 to 2026
$8.9M
Dr. Salma Jabbour’s NCI Research Specialist (Clinician Scientist) Award (R50)R50CA275877 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Salma Jabbour · 2023 to 2026
$785k
NCI NIH HHS R50 CA275877NCI NIH HHS U54 CA273956
6 · The paper itself

Abstract

Metastasis-directed therapy (MDT) is an emerging treatment option for metachronous oligometastatic castration-sensitive prostate cancer (omCSPC) and can delay time to progression and the need to initiate androgen deprivation therapy (ADT). However, optimal ways to synergize MDT and ADT are not known, and better personalization of MDT is needed. We examined the role of combined ADT and MDT and the ability of genomic alterations to provide prognostic and predictive information regarding response to MDT. We found that high-risk (HiRi) mutations in TP53, BRCA1/2, ATM, and Rb1 are poor prognostic markers in omCSPC. In addition, patients harboring HiRi mutations experienced greater benefit from addition of ADT to MDT, indicating that these alterations are predictive biomarkers for treatment intensification. Our results suggest that genetic biomarkers might aid in treatment personalization for patients with omCSPC.

Indexed as

Androgen AntagonistsProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAgedAtaxia Telangiectasia Mutated ProteinsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinGenomicsHumansMaleMiddle AgedMutationNeoplasm MetastasisPrognosisRetinoblastoma Binding ProteinsAndrogen AntagonistsAtaxia Telangiectasia Mutated ProteinsATM protein, humanBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanRB1 protein, humanRetinoblastoma Binding ProteinsTP53 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein LigasesCastration-sensitive prostate cancerGenomicsMetastasis-directed therapyOligometastasisPersonalized medicine

Identifiers

PMID40976747
PMCPMC13401512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.